New hope for advanced cancer: OBI-902 trial launches
Disease control
Recruiting now
This study tests a new drug called OBI-902 in people with advanced solid tumors that have not responded to standard treatments. The trial has three parts: first, finding the safest dose; second, checking how well it works in certain cancers; and third, comparing doses to pick the…
Phase: PHASE1, PHASE2 • Sponsor: OBI Pharma, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC